OBJECTIVE -Discordances between HbA 1c and other measures of glycemic control are common in clinical practice and remain unexplained. We developed a measure of discordance between HbA 1c and fructosamine (FA) (glycosylated serum proteins) to conduct a systematic evaluation. We termed this the glycosylation gap (GG) and sought to determine its relationship to diabetic nephropathy. RESULTS -GG had a broad distribution (range, Ϫ3.2% to 5.5%); 40% of samples had values indicating major differences in prediction of complications risk by the measured versus predicted HbA 1c . GG was highly correlated (r ϭ 0.81) between measurements repeated in 65 patients 23 Ϯ 2 weeks apart, indicating that the discordances are reliable and not explained by differences in turnover of underlying proteins. In 40 patients with type 1 diabetes of Ն15 years' duration, an increase in GG by 1% was associated with a 2.9-fold greater frequency of increasing nephropathy stage (P ϭ 0.0014). GG was Ϫ0.8 Ϯ 0.2% in subjects with no nephropathy, Ϫ0.3 Ϯ 0.2% with microalbuminuria/hypertension, and 0.7 Ϯ 0.3% in subjects with proteinuria or renal dysfunction (P Ͻ 0.05). GG correlated better with nephropathy than did either HbA 1c or FA alone in this population.
H
bA 1c is regarded as the gold standard for measurement of glycemic control and is invaluable in the treatment of diabetic patients. It is a predictor of diabetic complications, and int e r v e n t i o n s t h a t r e d u c e H b A 1 c correspondingly reduce the risk of complications (1-4). Whereas the overall utility of HbA 1 c is beyond question, discordances between HbA 1c and other measures of glycemic control are commonly encountered (5-7) and are important because of the millions of yearly HbA 1c measurements. Discordances between HbA 1c and other clinically used biochemical measures of glycemic control have often been attributed to inadequacies or poor reliability of glucose selftesting and reporting or artifacts (5-8). Despite newer, more reliable technology, however, significant differences between measures of plasma glucose and glycemia estimated from HbA 1c are still encountered. The 6-to 12-week time frame over which HbA 1c equilibrates is an important consideration when comparing with shorter-term measures of plasma glucose, but temporal factors may not entirely account for persistent discordance (9 -15) .
The question arises whether discordances between HbA 1c and other measures of glycemia are due to physiologic processes consistent within individuals over time. If this is the case, it is plausible that variation among diabetic patients in the intracellular glycation of proteins, independent of plasma glycemia, could affect the frequency of diabetic complications. We therefore wanted to test whether the discordance between HbA 1c and a simple measure of integrated plasma glucose was reliable and bore a relationship to the frequency of a major complication, diabetic nephropathy. An important difference between plasma glucose and HbA 1c is that the former reflects the physiology of glucose in the extracellular space, whereas HbA 1c reflects nonenzymatic glycosylation (and depends on glucose concentration) in the intraerythrocyte compartment. We therefore selected fructosamine (FA) for comparison because it represents a clinically accessible measure of nonenzymatic glycation of proteins in the same compartment as plasma glucose, and should integrate plasma glucose fluctuations. The common perception is that FA results differ from HbA 1c exclusively because of the difference in turnover times of the underlying glycation targets, hemoglobin versus serum proteins. The difference in physiologic compartments reflected in FA and HbA 1c has not been the object of interest. It was therefore important to exclude the effect of the difference in turnover time by evaluating the reliability of discordances over a greater time than that in which the turnover of red cells or most serum proteins occurs. The study was conducted with prospective collec-
tion of HbA 1c and FA in the population, with assessment of diabetic nephropathy based on chart review. In subjects with repeated measurements of HbA 1c and FA, the first and second pairs of values were used to examine variation in GG with time. If GG represented random variation in the HbA 1c -FA regression or resulted from differing time windows of exposure of serum albumin and the erythrocyte to glucose, consistency would not be expected.
RESEARCH DESIGN AND METHODS

HbA
Data were analyzed using JMP statistical software (SAS Institute, Cary, NC).
Nephropathy staging
The analysis of nephropathy was performed in a subset population with type 1 diabetes of Ն15 years' duration according to the following criteria: Grade 0, normal renal function: urinary microalbumin Յ20 g/min (24-h urine) or Յ17.9 g/mg creatinine (spot urine); diastolic blood pressure Ͻ95 mmHg without antihypertensive therapy.
Grade 1, microalbuminuria or hypertension: urine microalbumin 20 -200 g/ min (24 h) or 17.9 -179 g/mg creatinine (spot); or diastolic blood pressure Ͼ95 mmHg; or treatment for hypertension.
Grade 2, advanced renal dysfunction: Ͼ200 g/min urinary microalbumin or Ͼ300 mg/24 h protein or serum creatinine Ͼ1.5 mg/dl.
Blood pressure was measured using a mercury sphygmomanometer with cuff size selected based on manufacturer's recommendation for arm diameter with the subject seated for 5 min.
Analytic methods
HbA 1c , FA, urinary albumin, protein, and/or creatinine, and serum creatinine were measured during routine clinical care without batching. HbA 1c was measured in the laboratory of the Health Alliance of Greater Cincinnati using highperformance liquid chromatography (HPLC) ion exchange (Tosoh, Tokyo, Japan) (interassay coefficient of variation 2.9% at HbA 1c 5.5%, 1.9% at HbA 1c 10.0%). According to the manufacturer, carbamylated Hb does not interfere with the determination of HbA 1c in this assay. Fructosamine was measured at Quest Diagnostics by autoanalyzer (Roche Diagnostics, Indianapolis, IN) with a nitroblue tetrazolium reaction, using a fructosepolylysine standard, interassay coefficient of variation 2%. Urinary microalbumin was measured by nephelometry, and urine protein was measured spectrophotometrically.
RESULTS
HbA 1c -FA regression HbA 1c and FA were highly correlated (r 2 ϭ 0.61) (Fig. 1 ) in a population with widely varying glycemic control (see demographics in Fig. 1 legend) : HbA 1c (mean ϮSD) was 7.9 Ϯ 2.2%, FA 367 Ϯ 98 mol/l. The degree of correlation is very similar to previous reports (7-12,14,16). The regression line did not differ whether determined on the whole population or with exclusion of patients with type 1 diabetes of Ͼ15 years' duration, who form the basis for later analyses. Although there is a high degree of correlation, it is evident that there is substantial scatter as well. There was no difference in HbA 1c and FA or the regression line between HbA 1c and FA or GG by sex.
Reliability and population variation of the glycosylation gap
To assess reproducibility of the glycosylation gap, we analyzed the relationship between consecutive determinations in 65 pairs of HbA 1c and FA collected 23 Ϯ 2 weeks apart (Fig. 2) . There was a strong correlation (r ϭ 0.81) between the first and second determinations, with a yintercept that did not differ from 0 and slope that was positive but not equal to 1. The paired measurements did not differ (t test). Based on that, the sign of GG ap- pears highly reproducible, and the magnitudes of repeated determinations closely related. This is demonstrated over a time frame long enough to exclude effects of the physiologic differences in albumin versus erythrocyte turnover on GG.
To better assess intraindividual variability in the relationship of HbA 1c to FA, the regression was plotted for individual subjects in whom multiple pairs of HbA 1c and FA data over a time series were available (Fig. 3) . The paired values could be highly correlated (r Ն 0.98 in each case shown) suggesting a fundamental physiologic relationship. The line of one subject (A) appears parallel to the population line, indicating that this individual's GG would be constant across the range of glycemic control. One example each is shown of subjects in whom the slope of the line is higher (B) or lower (C) than that for the population. These predict average GGs within subjects that are positive in both cases but rising in one case and falling in the other case as glycemic control deteriorates. This is a potential factor in the variability in magnitude of GG while the sign is more reproducible.
The distribution of GG was determined in the original population from which the measure was derived and in the subpopulation with type 1 diabetes of Ն15 years' duration. The distribution of GG in the original population was skewed toward positive values and not normally distributed (Shapiro-Wilk test), with median -0.20% and 25th and 75th percentiles of -0.8% and 0.7% (not shown). In the long-term type 1 diabetes population, the distribution of GG was normally distributed with mean Ϯ SD Ϫ0.3% Ϯ 1.0% (not shown). Twenty-seven (17%) and 36 (23%) patients had GG Ͼ1% below or above zero, respectively, indicating a large population in whom prediction of complications on the basis of measured HbA 1c would differ substantially from that based on HbA 1c predicted from FA and the HbA 1c -FA regression. An HbA 1c decrement of 1-2% has reduced microvascular complications 40 -70% (2-4).
The glycosylation gap and nephropathy stage Among subjects with type 1 diabetes of Ն15 years' duration, the glycosylation gap was Ϫ0.7 Ϯ 0.2% with no nephropathy, Ϫ0.3 Ϯ 0.2% with microalbuminuria/hypertension, and 0.7 Ϯ 0.3% with proteinuria or severe renal dysfunction (Fig. 4) (P ϭ 0.005 by ANOVA; P Ͻ 0.05 for a difference between stage 0 and stage 2 by post-hoc Student's t test). By ordinal logistic regression, there was a highly significant relationship found between GG and nephropathy: the relative frequency of advancing nephropathy stage, normalized per HbA 1c unit, for GG was 2.9-fold (95% CI 1.4 -6.1; P ϭ 0.003); for HbA 1c , 1.3 (0.86 -1.9; P ϭ 0.21); and for FA 0.84 (0.59 -1.2; P ϭ 0.31). Of the 10 patients described as stage 2, a single patient was in chronic renal failure (not on dialysis) and one other patient had had a renal transplant. Relationships between nephropathy stage and either HbA 1c or FA did not reach significance. After correction for the effects of urinary protein loss, the relative frequency of advancing nephropathy stage, normalized per HbA 1c unit, for GG was 2.2-fold (95% CI 1.1-4.5; P ϭ 0.03). Mean Ϯ SE FA was 387 Ϯ 11 mol/l for all the subjects with type 1 diabetes of Ն15 years' duration, 394 Ϯ 17 mol/l in subjects with no nephropathy, 378 Ϯ 21 mol/l in those with microalbuminuria, and 386 Ϯ 23 mol/l in those with proteinuria, indicating no significant decline with worsening nephropathy (P ϭ 0.82). HbA 1c was 7.9 Ϯ 0.2% in the entire subpopulation with diabetes of Ն15 years' duration, 7.6 Ϯ 0.4% in subjects with no nephropathy, 7.7 Ϯ 0.4% with microalbuminuria, and 8.7 Ϯ 0.5% with proteinuria (P ϭ 0.15). The regression between GG and nephropathy was not altered when HbA 1c , FA, or duration of diabetes were included as factors in the analysis. Results were similar when GG was expressed as a percentage of measured HbA 1c , which would normalize for HbA 1c absolute magnitude. There was no effect of sex detected on multivariate ordinal logistic regression between glycosylation gap and nephropathy.
If the glycosylation gap were substantially altered by the presence of diabetic nephropathy, the population with longterm diabetes, which includes those with nephropathy, might be expected to have higher glycosylation gaps than those with short-duration type 1 diabetes. However, no difference was detected in the glycosylation gap between the subjects with type 1 diabetes of long versus short duration (Ϫ0.4 Ϯ 0.2% vs. -0.5 Ϯ 0.1%; P ϭ 0.63, Wilcoxon test).
We sought to model the effects of glycated proteinuria on glycosylation gap. There is evidence that glycated albumin is no more likely to be lost in the urine than nonglycated albumin (17) (18) (19) . At total body albumin daily synthesis of 13.9 g/person reported in patients with type 1 diabetes and nephropathy (20) , GG would be altered by 0.1% for each 213 mg/24 h of urinary albumin at the group mean FA of 386. Albumin constitutes ϳ85% of the total urinary protein in diabetic nephropathy (21) . When these factors were taken into account, the relative frequency of advancing nephropathy stage with GG remained significant, 2.2-fold per HbA 1c unit (95% CI 1.1-4.5; P ϭ 0.03).
CONCLUSIONS
This study demonstrates that discordances commonly found among measures of glycemic control can be persistent and stable and related to a major complication of diabetes, nephropathy. The fact that the glycosylation gap, the HbA 1c -FA residual, correlates so well with a major complication of diabetes suggests shared factors between the origin of the discordance and the pathogenesis of the disease process. What does it mean that this study did not detect a relationship between HbA 1c and nephropathy? The population was relatively small and the study may not have had the power to detect that effect.
The glycosylation gap could be affected by the production and disappearance rate of glycated hemoglobin, glycated serum proteins, or both. We are particularly interested in analyzing the variations found in otherwise healthy people with diabetes in whom urinary protein loss is not an issue, specifically whether it results predominantly from a gradient in protein nonenzymatic glycosylation between the two physiologic compartments. It is, however, possible that variations in the GG could be a consequence, rather than a marker or predictor, of nephropathy due to effects of proteinuria on protein turnover and FA. Patients with a high GG and high risk of nephropathy have a low FA in relationship to the HbA 1c . This would be the direction anticipated if albumin has a shorter survival time in the circulation, upon loss of glomerular selectivity (18, 19) . However, the lack of significant difference in FA by nephropathy stage is itself an argument that the findings are not explained by reduced FA in the group with urinary protein loss. Urine protein loss can contribute to the GG and can have a quantitatively important effect when present in the high microalbuminuric range. However, our modeling shows that a rise in glycosylation gap remained associated with increased nephropathy frequency even when such effects were taken into account. The observed effects are not solely a consequence of urinary protein loss. We were unable to detect a difference in GG by duration of type 1 diabetes expected if the gap is a consequence of nephropathy. Markedly positive GG values were found in patients with shorter durations of diabetes than those included in the complications analysis who do not currently have significant nephropathy, indicating that nephropathy is not necessary to have a positive GG. Other unrelated disease states that markedly perturb Hb or serum protein turnover could affect the GG, so these measurements must be assessed in clinical context. These data demonstrate correlation between GG and nephropathy, not prediction. Hempe et al. (22) and McCarter et al. (23) have demonstrated that the hemoglobin glycosylation index, an analogous measure of discordance between self glucose-monitoring and HbA 1c , is also consistent and predicts both retinopathy and nephropathy, suggesting that the differences between extracellular and intracellular measures of glycemic control may precede nephropathy. Future prospective studies could delineate the cause-andeffect relationship in the regression of GG on nephropathy stage. The parallel between the Hempe et al. studies and ours that the discordances are between HbA 1c and extra-erythrocyte measures of glycemic control strongly favors the concept that the discordances are systematic and potentially relevant to the pathophysiology of diabetic complications. It would also argue for an underlying mechanism that is related to the difference between the erythrocyte and plasma compartments. If, under carefully selected circumstances, the GG results predominantly from a gradient in protein nonenzymatic glycosylation between the plasma and intracellular compartments, it could represent previously unrecognized gradients in glucose concentration or factors that differentially alter the forward or reverse rates of nonenzymatic glycosylation. Variation in oxidation-reduction status (24, 25) would be one important candidate. We have recently demonstrated population heterogeneity in the gradient established across the erythrocyte membrane by a radiolabeled nonmetabolizable glucose analog, 3-O-methylglucose, incubated with glucose-depleted erythrocytes (26) . This supports the concept of variability in the red cell membrane glucose gradient. The data do not distinguish among these or other candidate mechanisms.
Several caveats: The population used for the complications analysis was a subgroup of the population in which GG was defined rather than an independent population. However, the regression generated with a subpopulation that did not overlap with that for the complications analysis was identical. The nephropathy end points were based on American Diabetes Association standard of care Clinical Laboratory Improvement Amendmentscertified routine clinical monitoring of patients, not research assays. Carbamylated hemoglobin can accumulate in erythrocytes of uremic patients (27) (28) (29) (30) (31) , and it is important to ensure that carbamylated Hb is not a confounder. Whereas the manufacturer indicates that carbamylated Hb does not affect the method used here, there is limited evidence challenging this assertion (32) . The urea nitrogen concentration was closely clustered in 38 of our 40 nephropathy analysis subjects, making a carbamylated Hb effect on these results unlikely (not shown). Most of the patients were at stable glycemic control when sampled, and Fig. 3 indicates that the HbA 1c -FA relationship can be extremely stable within subjects. If samples are collected early after changes in glycemic control, that could reduce the GG stability over time.
Shortened red cell survival associated with renal failure would have an effect opposite to the relationship found, making it unlikely to be a contributor to our findings.
In summary, we observed consistent discordances between HbA 1c and an extra-erythrocyte measure of glycemic control, FA. Changes in glycosylated proteins resulting from nephropathy do not appear to explain these findings but have not been ruled out conclusively. When this discordance is quantitated in the form of a glycosylation gap, it correlates with the frequency of a major microvascular complication of diabetes. We propose that the glycosylation gap will be useful as a research probe quantitating variation between the two underlying tests of glycemic control to identify sources of population variation in diabetic complications beyond glycemic control per se. Prospective studies will be necessary to determine whether repeated determinations should alter decision-making regarding risk for future complications in the individual patient.
